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A B S T R A C T
New strategies to characterize the eﬀects of engineered nanomaterials (ENMs) based on omics technologies are
emerging. However, given the intricate interplay of multiple regulatory layers, the study of a single molecular
species in exposed biological systems might not allow the needed granularity to successfully identify the
pathways of toxicity (PoT) and, hence, portraying adverse outcome pathways (AOPs). Moreover, the intrinsic
diversity of diﬀerent cell types composing the exposed organs and tissues in living organisms poses a problem
when transferring in vivo experimentation into cell-based in vitro systems.
To overcome these limitations, we have proﬁled genome-wide DNA methylation, mRNA and microRNA ex-
pression in three human cell lines representative of relevant cell types of the respiratory system, A549, BEAS-2B
and THP-1, exposed to a low dose of ten carbon nanomaterials (CNMs) for 48 h. We applied advanced data
integration and modelling techniques in order to build comprehensive regulatory and functional maps of the
CNM eﬀects in each cell type.
We observed that diﬀerent cell types respond diﬀerently to the same CNM exposure even at concentrations
exerting similar phenotypic eﬀects. Furthermore, we linked patterns of genomic and epigenomic regulation to
intrinsic properties of CNM. Interestingly, DNA methylation and microRNA expression only partially explain the
mechanism of action (MOA) of CNMs. Taken together, our results strongly support the implementation of ap-
proaches based on multi-omics screenings on multiple tissues/cell types, along with systems biology-based
multi-variate data modelling, in order to build more accurate AOPs.
1. Introduction
Since the rapid expansion of the nanotechnology, nanotoxicology
has emerged as an important discipline to ensure safe innovation.
Nanomaterial toxicity is currently investigated by extensive animal
studies, but more and more emphasis has been put into in vitro-based
approaches as well as in understanding the relevant molecular me-
chanisms involved in engineered nanomaterials (ENMs) exposures.
Several studies have already addressed the importance of proﬁling the
transcriptome of exposed biological systems for understanding the
molecular alterations caused in response to ENMs exposure (Nel, 2013;
Nel et al., 2013; Marx-Stoelting et al., 2015; Jennen et al., 2011;
Robinson et al., 2012; Tralau et al., 2015). However, the separate in-
vestigation of certain molecular domains does not allow to build a
thorough landscape of the ENMs mechanism of action (MOA). Hence, to
better model and predict the long-term adaptation of an exposed bio-
logical system, more comprehensive and integrative analyses, inter-
rogating multiple molecular districts, need to be carried out. Still, to the
best of our knowledge, there have not yet been to date comprehensive
attempts to study ENMs MOA using a multi-omics approach.
In humans, exposure to ENMs mainly happens in production en-
vironments via the airways. We and others already showed that ENMs
are able to exert toxic eﬀects on the respiratory system, by using animal
exposure models (Kinaret et al., 2017a; Rydman et al., 2015; Rydman
et al., 2014). Apart from the pathological responses, ENMs MOA has
been investigated in diﬀerent tissues (Kinaret et al., 2017b; Fröhlich,
2017; Costa and Fadeel, 2016), by analyzing the molecular perturba-
tions that these materials are able to induce on the normal
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transcriptional program of exposed cells and tissues.
However, responding to the constant pressure in developing reliable
and eﬃcient alternative screening methods, many studies tried to
predict the potential ENMs eﬀects in vivo by analyzing their eﬀects in
vitro (Drasler et al., 2017; Braakhuis, 2015; Törnqvist et al., 2014;
Bachler et al., 2015). We recently demonstrated that carbon based
nanomaterials have distinct transcriptional MOA between in vivo and in
vitro experimental settings and that commonalities are to be found by
using comprehensive gene network models (Kinaret et al., 2017b).
Changes in the levels of gene transcription can be usually appre-
ciated at short term and acute responses, but they are less eﬀective in
explaining longer eﬀects of ENMs exposure, which are of greater in-
terest to model the real-life exposure scenarios. More recently, a
number of studies have focused on the alterations caused by ENMs
exposure at the level of DNA methylation (Chen et al., 2017; Sierra
et al., 2017). Investigating epigenomic mechanisms, such as alteration
of DNA methylation and microRNA expression, can indeed capture
more persistent molecular changes underlying long-term transcrip-
tional programs.
In this study, we exposed three human lung-derived cell lines, re-
presentative of major cell types of the respiratory system, to sublethal
doses of ten diﬀerent carbon nanomaterials for two days, assessed their
genome-wide eﬀects on three distinct molecular layers simultaneously,
the DNA methylation, the microRNA and mRNA expression, and
modelled their functional interactions.
By performing a comprehensive integrative analysis, we provide a
broad picture of the cross-talk between regulatory factors (DNA me-
thylation and miRNAs) and mRNA deregulation following the exposure
to carbon nanomaterials. Further, we show how the MOA of the same
carbon nanomaterials vary according to the cell type/tissue of origin,
thus highlighting the importance of considering a heterogeneous and
representative set of cell types for a target organ when testing the ef-
fects of engineered nanomaterials in vitro.
2. Results and discussion
2.1. Experimental setup
In this study, we investigated the eﬀects of ten well characterized
carbon nanomaterials (CNMs, Table 1) on three cell lines of human
alveolar epithelium (A549), bronchial epithelium (BEAS-2B) and mac-
rophages (PMA-diﬀerentiated THP-1). We focused on low dose ex-
posure for 48 h and thoroughly characterized their eﬀects by inter-
rogating three diﬀerent molecular districts genome-wide, the mRNA,
microRNA, and DNA methylation.
2.2. Cell viability and cytotoxicity
Most of the in vitro exposure studies concentrate on acute eﬀects
(usually within 24 h), with relatively high ENM concentrations that do
not correlate well with in vivo conditions or with the human long-term
exposure scenarios (Landsiedel et al., 2014). Gangwal et al. estimated
that a life-time (45 years) exposure duration of the alveolar mass re-
tention for TiO2, Ag and CNT ranges from 10 to 50 μg/cm2. Based on
the proposed model, the mass retention corresponds to in vitro studies
with relatively high ENM concentrations ranging from 30 to 400 μg/ml
(Gangwal et al., 2011).
Here, nanomaterial exposures to THP-1, BEAS-2B and A549 cell
lines decreased the cell viability in dose-dependent manner, especially
with the three highest tested doses of 50, 100 and 500 μg/ml (Figs.
S1–S3). Lactate Dehydrogenase (LDH) release was concordant with the
cell viability measures in BEAS-2B and THP-1 showing a clear LDH
increase after 48-h CNM exposure at the highest doses (Figs. S2, S3),
while A549 seemed to be the least responsive cell line (Fig. S1). In
particular, THP-1 was the most sensitive (Fig. S3), showing slightly
more elevated LDH levels, when compared to other cell lines. This was
especially observed with GNF and MIT_MW, that have a known toxic
potential. The lower doses, ranging from 0.1 to 5 μg/ml, did not to
cause major responses, with highly similar LDH levels and consistent
cell viability. Given these results, the 10 μg/ml concentration was
chosen for showing no signiﬁcant cell death, but still indicating some
responses as compared to the baseline, thus corresponding more to a
subchronic rather than acute response.
2.3. Molecular eﬀects
In addition to a variety of in vitro end point assessments, OMICS
approaches allow for comparison of diﬀerent in vitro systems as well as
better correspondence to in vivo exposure scenarios (Kinaret et al.,
2017b; Drasler et al., 2017). Combination of diﬀerent OMICS methods
can inform more thoroughly about ENMs MOA, which could be further
used in ENM grouping approaches, as suggested by Riebeling et al.
(2017). Gene expression proﬁling of co-cultures and 3D cultures, as
well as systems taking into account exposure route such as Air Liquid
Interface cultures (Latvala et al., 2016; Kletting, 2017), better resemble
the in vivo exposure scenarios, but before clear conclusions about the
ENM MOA can be drawn, cell type-speciﬁc responses need to be ad-
dressed by omics approaches (Drasler et al., 2017; Snyder-Talkington
et al., 2015). The importance of multi-omics approaches in the study of
MOA of toxicants has been demonstrated in several toxicogenomics
studies (Jayapal, 2012; Gavin, 2016). On the other hand, focusing on
one molecular layer alone might not be suﬃcient to fully describe the
MOA of an external stimulus (Huang et al., 2017). The analysis of a
single molecular layer can reveal information that is mainly related to
Table 1
Tested nanomaterials and their characteristics.
Material name Producer Acronym Type Length (nm) Diameter (nm) Surface area (m2/
g)
Aspect ratio References
Carbon black (Evonik) Evonik industries/
Degussa
CBL Particle 14 14 265 1 (Vippola et al., 2009)
Fullerene C60 (MTR) MTR Ltd. FUL Sphere 100 100 20 1 (Lehto et al., 2014)
Graphite nanoﬁbers (Sigma) Sigma-Aldrich GNF Fiber 10,000 140 32 71.4 (Vippola et al., 2009)
Singlewalled carbon nanotube (Sigma) Sigma-Aldrich SIG_SW Tube 50,000 1.1 567 45,454 (Vippola et al., 2009)
Singlewalled carbon nanotube (SES) SES research SES_SW Tube 1500 2 436 750 (Vippola et al., 2009)
Multiwalled carbon nanotube (Bayer) Bayer material science BAY_MW Tube 1000 14.5 204 68.9 (Vippola et al., 2009)
Multiwalled carbon nanotube (Mitsui) Mitsui & Co. MIT_MW Tube 13,000 50 22 260 (Kinaret et al.,
2017a)
Multiwalled carbon nanotube (SES) SES research SES_MW Tube 1500 20 60 75 (Vippola et al., 2009)
Multiwalled carbon nanotube
(cheaptubes)
Cheaptubes Inc. CHT_MW Tube 30,000 11.5 180 2608 (Rydman et al.,
2015)
Multiwalled carbon nanotube (Sigma) Sigma-Aldrich SIG_MW Tube 100,000 15 119 6666 (Vippola et al., 2009)
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reactive processes but not to the causative molecular processes, the
integration of diﬀerent layers, on the other hand, gives the possibility to
describe the chain of causative changes involved in determining the
observed phenotypes (Hasin et al., 2017). Here, we inferred the MOA of
a panel of ten CNMs on three cell lines representative of major cell types
of the respiratory system, A549, BEAS-2B and THP-1, by interrogating
three molecular districts and systematically integrating their omics-
derived data (Fig. 1).
We deﬁned the MOA of each CNM in each cell line as the ensemble
of molecular and cellular pathways signiﬁcantly altered after integra-
tion of genome wide DNA methylation, miRNA expression and gene
expression.
By following a commonly accepted scheme of gene regulation
(Consortium, 2012), we tested the hypothesis that hypomethylation in
the gene promoter, paired with hypermethylation of the gene body
and/or the under-expression of a targeting microRNA could explain
gene upregulation. Likewise, hypermethylation of the promoter region
and/or over-expression of a targeting microRNA could underlie gene
down-regulation. For each exposure, we ranked the genes based on the
concatenated regulatory eﬀects of the three analyzed layers. Next, we
inferred modules of high ranking genes that were enriched for protein-
protein interactions and derived the enriched KEGG pathways. We then
measured the eﬀects of each nanomaterial in each cell line in terms of
number of altered pathways as well as the direction of gene expression
in these pathways.
2.4. Cell lines respond diﬀerently to CNM exposure
Based on the magnitude of the molecular events, overall, BEAS-2B
cell line was the most sensitive to CNM exposure followed by THP-1,
while A549 exhibited the smallest MOA (Fig. 2) (Scala et al., 2018).
Interestingly, the MOA of BEAS-2B was largely unbalanced towards the
induction of gene expression, while it was more balanced between the
amount of up- and down-regulation in the other cell lines. BEAS-2B cell
line, derived from normal human bronchial epithelium, might be more
sensitive to stimuli than the other two cell lines considered in this study
(A549 and THP-1), which are cancer-derived. Likewise, it is possible to
hypothesize that the steady state transcriptome of non-cancerous BEAS-
2B is generally kept at lower levels of activation. When analyzing the
eﬀects of the individual exposures in detail, considered at the level of
the altered pathways, it appeared evident that fullerene (FUL) and
carbon black (CBL), the spherical materials with the smallest aspect
ratio, had a very marginal impact on all the three cell lines (Fig. 2). On
the contrary, all the nanotubes investigated in this screening caused
alteration of many molecular pathways in all the three cell lines, with
the exception of SES_SW, to which A549 cells were essentially un-
responsive. Interestingly, graphite ﬁbers did not cause remarkable
molecular alterations on the THP-1 cells, but had an impact to other
two cell lines.
Our results overall suggest that same exposures may have sig-
niﬁcantly diﬀerent MOA in diﬀerent cell types. Speciﬁc steady-state
transcriptional patterns of diﬀerent cell types inﬂuence the cellular
responses, signaling cascades and thus the CNM MOA. For this, it is
expected that non-professional phagocytes, the epithelial cells BEAS-2B
and A549, sense foreign substances diﬀerently than the professional
phagocytes, such as macrophage-like cells derived from the THP-1 cell
line. A549 cells originate from basal cells of the alveolar region (type II
alveolar epithelial cells), whereas BEAS-2B cells are from bronchioles
and trachea (Lieber et al., 1976; Schlinkert et al., 2015). The original
anatomic location of the cells in the pulmonary tract reasonably also
inﬂuences how environmental signals are processed. Epithelial cells
from bronchioles are more likely to be directly exposed to foreign
particles in the respiratory system in vivo, whereas basal cells, located
under the ﬁrst epithelial layer or in the alveolar regions, might not be
aﬀected by outer threats as rapidly and as severely.
Another diﬀerence between the two epithelial cell lines considered
in this study, are organelles called lamellar bodies. Studying the uptake
of diﬀerent sized ultraﬁne particles of TiO2 in A549, Singh and colla-
borators noted that the uptake was limited to aggregated particles,
found inside the lamellar bodies and membrane bound vacuoles (Singh
et al., 2007). Similar results were regained in another study by Stearns
et al., where the uptake of TiO2 particles was limited to aggregates
found inside the lamellar bodies of the A549 cells after 24 h exposure
(Stearns et al., 2001). They also postulated that single ultraﬁne particles
are possibly not a target of phagocytosis by type II epithelium, but are
internalized as aggregates, as also concluded by Churg et al. (Churg
et al., 1998) Type II alveolar cells, including A549 cells, are the main
producers of pulmonary surfactants, such as phospholipids that reduce
the surface tension. The secreted surfactants cover the foreign particle
surface by forming a biological corona (Sund et al., 2011). This protein-
Fig. 1. Omics data integration and inference of mechanism of action procedure. (A) raw data from the three omics layers (DNA methylation, mRNA and miRNA
expression) is preprocessed, and diﬀerential analysis for each layer is performed separately; (B) p-values and fold changes from each data layer are mapped to
promoter and gene bodies of UCSC genes, combined in order to deﬁne ranks of genes, and used to extract high scoring gene modules; (C) enriched KEGG pathways
are derived for the obtained modules in each exposure.
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lipid coating can, in turn, change the modality of presentation of na-
noparticles to the A549 cells, possibly explaining the lower level of
molecular alterations observed in this study (Hohlfeld, 2002). Else-
where, A549 cells were the least susceptible to diﬀerent gold and silver
nanomaterials as compared to BEAS-2B and primary lung epithelial
cells, in line with our observations (Schlinkert et al., 2015). These re-
sults from several previous studies, do explain why also in our study set
up, the A549 cell line was the least responsive. Bronchial epithelial cells
such as BEAS-2B cell line on the other hand, have most likely evolved to
have several response mechanisms, being among the ﬁrst line of de-
fense, constantly encountering a variety of inhaled particles. For ex-
ample, it has been demonstrated by Zhang et al., that BEAS-2B cell line
is more sensitive to cigarette smoke-induced cytotoxicity when com-
pared to A549 (Zhang et al., 2017).
2.5. DNA methylation and microRNA expression partially explain CNM
MOA
Next, we tested the hypothesis that the MOA of CNM would be
explained by the regulatory model involving alteration of the DNA
methylation at the level of the gene promoters and the regulation of
microRNA expression (Fig. 3) (Scala et al., 2018).
Our results conﬁrm that overall, the regulatory model exploited
here explains a fair amount of the CNM MOA (62% in BEAS-2B, 53% in
THP-1, and 50% in A549). When we focused on the proportion of the
MOA resulting in gene induction, we observed a larger concordance in
BEAS-2B (79%) and in THP-1 (65%) as compared to A549 (33%). On
the contrary, the amount of the MOA proportion involving gene re-
pression compatible with the methylation/miRNA regulatory model
was highest in A549 (68%), moderate in THP-1 (39%), and minute in
BEAS-2B (8%). Interestingly, the upregulated MOA of carbon black and
Cheaptubes in A549 as well as SIG_MW in BEAS-2B are not explained at
all by the regulatory model. Similarly, the downregulation of the
Cheaptubes in BEAS-2B is entirely discordant with the tested regulatory
model.
Omics studies are an emerging standard in the analysis of MOA of
toxicants. However, focusing on a single molecular layer is not always
suﬃcient to completely infer gene regulation patterns (Long et al.,
2017) and the consequent alterations of the related molecular path-
ways. For example, in a similar experimental setting, where THP-1 cells
were exposed to multi-walled carbon nanotubes, Oner et al. (Öner et al.,
2016) inferred several pathways to be induced starting from genes
showing promoter hypomethylation. However, our results indicate that
the whole picture obtained through a multilayer approach is more
complex and, especially in a “low-dose-short-time” setting, cannot be
successfully portrayed by looking at a single molecular layer alone, as
conﬁrmed by the signiﬁcant percentage of genes in our results, whose
expression alteration does not follow the canonical regulation by DNA
methylation.
2.6. Comparison of CNMs MOA
We used the motifs of pathway alteration to compute similarities of
CNM MOA (Fig. 4). The patterns of MOA similarity in A549 were not
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Fig. 2. Bar plots reporting the number of up-regulated (red) and down-regulated (green) pathways in each exposure in the three cell lines. Pathway regulation is
deﬁned based on the median expression fold change of genes belonging to the pathway. (For interpretation of the references to color in this ﬁgure legend, the reader
is referred to the web version of this article.)
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easily attributable to CNM intrinsic properties. However, in this cell
line, the two most similar MOA were exacerbated by SIG-SW, the ma-
terial with the smallest diameter and highest surface area, and the
known hazardous MIT_MW, which selectively induced pathways re-
lated to immune response (Fig. 4A).
Especially “environmental information processing” and “cellular
processes” such as focal adhesion and cell adhesion were upregulated in
BEAS-2B with several materials. It is known that induction of cell ad-
hesion molecules, such as ICAM and VCAM are induced by pro-in-
ﬂammatory cytokines, mediating leukocyte adhesion and extravasation
(Atsuta et al., 1997; Veranth et al., 2004). In BEAS-2B we could ap-
preciate a clear distinction between the particle and spherical materials,
carbon black and fullerene, and the tubes and ﬁbers (Fig. 4B). This
diﬀerence was particularly evident at the level of the pathways related
to regulation of actin cytoskeleton and focal adhesion. These pathways
are altered by all the nanotubes and graphite nanoﬁbers, but not by
carbon black nanoparticles and fullerene nanospheres (Scala et al.,
2018).
The uptake mechanism of BEAS-2B cells might involve an endocytic
pathway in a size-dependent manner, as suggested by Kim et al. (Kim
et al., 2011; Nymark et al., 2013) This might explain why most of the
nanomaterials in our panel, being much longer than 40 to 50 nm, might
not be internalized by BEAS-2B, but most likely trigger signaling cas-
cades through surface contact. This is supported by high activation of
ECM–receptor interaction, focal adhesion and cell adhesion molecules
(CAMs), as well as regulation of actin cytoskeleton in BEAS-2B cells
when exposed to tube-structured CNM. In contrast, all the three non-
tube-structured nanomaterials, fullerene, graphite and carbon black, do
not activate ECM receptor-interaction-pathways, regulation of actin
cytoskeleton or focal adhesion (Scala et al., 2018). The small size of
fullerene and carbon black particles might result in reduced interaction
with the cell surfaces and overall signaling cascades. Interestingly, also
the other non-tubular material, GNF, shows similar pattern in all three
cell types. Moreover, poor ability of both type I and II epithelial cells to
uptake carbon black particles has already been described in vivo
(Corrin, 1970).
Interestingly cAMP signaling pathway is activated by SIG-SW, SIG-
MW and SES-SW in BEAS-2B and THP-1 cells, but in opposite directions
(Fig. 5) (Scala et al., 2018). Single-walled materials have the smallest
diameter, whereas SIG-MW has the longest average length. Several
signaling pathways are altered in opposite directions between the two
cell lines, suggesting distinct sensing molecular mechanisms and re-
ceptor activation. For instance, the expression of genes belonging to the
PI3K–Akt signaling pathway were found to be induced by all the na-
notube materials in BEAS-2B. Instead, the same pathway was repressed
by exposure with SIG-SW, CHT_MW, SIG-MW, SES-SW and MIT_MW
nanotubes in THP-1 (Fig. 5) (Scala et al., 2018). These results suggest
that, while in epithelial cells the regulation of PI3K-Akt signaling
pathway genes is achieved by directly altering the DNA methylation
levels, in THP-1 other epigenetic mechanisms may mediate a similar
modulation of the same genes. Since alteration of the DNA methylation
levels is thought to be more stable than other regulatory signals, it is
reasonable to hypothesize that the induction of PI3K-Akt signaling
pathway genes in epithelial cells could persist for longer time after
exposure. These results are in concordance with the observations by
Labib et al., who pinpointed transcriptomic alterations of PI3K-Akt
signaling pathway in vivo as a driving event of long term MIT_MW ex-
posure (Labib et al., 2015).
Similarly, we observed hypermethylation of the genes of the leu-
kocyte transendothelial migration pathway in both epithelial cell lines
when exposed to MIT_MW. Interestingly also Labib et al. concluded that
the expression of the leukocyte extravasation pathway genes was still
highly altered 56 days after lung exposure with the same material in
mice in vivo (Labib et al., 2015). Our results further support the hy-
pothesis that alteration of gene expression accompanied by DNA me-
thylation changes could drive long term adaptation in exposed biolo-
gical systems.
In THP-1, the MOA of CNM with high aspect ratio and higher dia-
meter were grouped together, respectively (Fig. 4C). Exposure with
higher diameter materials mainly altered pathways related to regula-
tion of inﬂammatory and immune responses (TNF, cytokine-cytokine
receptor interactions, IL17, RIG-I receptor and NOD-like receptor sig-
naling pathways) (Fig. 5) (Scala et al., 2018). On the other hand, ex-
posure to higher aspect ratio CNM produced changes in pathways of the
intracellular signaling.
The endocrine system related pathways are altered in THP-1 and
BEAS-2B, but not A549, by the CNMs with high surface area and aspect
ratio, and small diameter, namely SIG_SW, CH, SIG_MW, SES_SW. In our
screening, THP-1 is the most susceptible to endocrine system pathways
alteration (Fig. 5) (Scala et al., 2018). Several ENMs have been shown
to act as endocrine disrupting compounds (EDCs). Couleau et al. de-
monstrated that several EDCs reduced phagocytosis of diﬀerentiated
THP-1 cells, and disturbed TNF-a, Il-1b and IL-8 cytokine secretions, as
well as decreased ERK ½ phosphorylation was associated to EDC
treatments (Couleau et al., 2015). Moreover, several studies have re-
ported similar results, showing that EDCs directly aﬀect the innate
immune system (Bennasroune et al., 2012; Ohnishi et al., 2008; Roy
et al., 2012; Watanabe et al., 2003).
Cancer pathways were mostly activated by the two epithelial cell
lines. It has been shown that BEAS-2B cell line can be malignantly
Fig. 4. Hierarchical clustering representing MOAs similarity of nanomaterials for each cell line. Distance between diﬀerent exposures is computed using the com-
plement of Jaccard index on shared positive and negative pathways. Clustering was performed using Ward's method.
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transformed in vitro via several compounds such as chromium, arsenite
and cigarette smoke (Zhao and Klimecki, 2014). Proteoglycans in
cancer-pathway was activated by most of the nanomaterials both, at the
level of RNA expression as well as methylation, excluding only
Cheaptubes and fullerene. The activation of proteoglycans, might also
indicate a phenotypic change in the BEAS-2B cell line, towards cancer
related signaling.
2.7. Conclusions
Here we show that the molecular alterations due to CNM exposure
are highly dependent on the cell type as well as the geometrical prop-
erties of the nanoparticles. When information concerning changes in
gene expression are systematically integrated with DNA methylation
and miRNA expression, better understanding of ENM MOA can be
drawn. Since epigenetic modulation is a molecular marker of long term
stable adaptation, the interpretation of ENM MOA is highly enhanced
by multi-omics approaches. This, in turn, helps in building more thor-
ough landscape of the molecular eﬀects caused by the exposure, thus
supporting the deﬁnition of more accurate ENM adverse outcome
pathways (AOPs).
3. Materials and methods
3.1. Nanomaterials and suspensions
Nanomaterials used in this study were previously characterized and
reported in NANOATLAS (Vippola et al., 2009) as well as in our pre-
vious publications (Kinaret et al., 2017a; Rydman et al., 2015; Rydman
et al., 2014; Palomäki et al., 2015). Providers and material character-
istics are reported in Table 1.
Nanomaterial suspensions were prepared by weighing the materials
into glass tubes and diluting them with 1% FBS-PBS to a stock con-
centration of 1mg/ml. The stock was sonicated 2× 15min in bath
sonicator (Elmasonic, USA) at room temperature, and additional 15min
to MIT_MW, GNF and FUL particles. Dilutions were prepared to corre-
sponding cell culture media (see below) supplemented with 1% FCS and
sonicated for 15min and vortexed before the exposures.
Fig. 5. Selected pathways resulting from each exposure grouped by pathway category on rows and by exposed cell line on columns. Red and green cells are associated
with signiﬁcantly enriched KEGG pathways (FDR adjusted hypergeometric p-value<0.05), grey cells stand for no signiﬁcant enrichment. Red cells are associated
with enriched KEGG pathways whose genes have a positive median log fold-change in the corresponding comparison, green cells are associated with KEGG pathways
whose genes have a negative median log fold-change in the corresponding comparison. Panel A reports mRNA expression median log fold-change directions, Panel B
reports methylation median log fold-change directions and Panel C reports miRNA expression median log fold-change directions. (For interpretation of the references
to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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3.2. Cell culturing and exposures
THP-1 cells (ATCC TIB-202) were grown in complete RPMI media,
supplemented with 10% FBS and 1% Ultraglutamine. BEAS-2B cells
(American Type Culture Collection through LGC Promochem AB (Borås,
Sweden)) were grown in LHC-9 media and A549 (ATCC CCL-185) cells
were grown in DMEM media including L-glutamine, supplemented with
10% FBS. Cells were grown in culturing ﬂasks (75 cm2) at 37 °C in
humidiﬁed atmosphere of 5% CO2. Exposures were performed in 12
-well plates, with concentration of 10 μg/ml in corresponding medias
supplemented with 1% FCS, as follows: THP-1: 800,000 cells per well
for RNA and DNA extractions, 900,000 cells/well to miRNA extractions;
BEAS-2B: 100,000 cells/well to RNA, DNA and miRNA extractions;
A549: 50,000 cells/well to RNA, DNA and miRNA extractions. THP-1
cells were diﬀerentiated with 50 nM PMA (phorbol-12-myristate-13-
acetate) for 48 h before nanomaterial exposure. Exposures were con-
ducted as triplicates with ﬁnal concentration of 10 μg of ENM/ml in
each well. The concentration of 10 μg/ml was chosen based on the cell
viability (ATP) and cytotoxicity (LDH) screenings, using 8 diﬀerent
concentrations (Figs. S1–S3). After 48-h incubation, the media was se-
parated and the cells were washed with PBS and harvested according to
the Qiagen AllPrep DNA/RNA extraction protocol (Qiagen, GmbH,
Hilden, Germany).
3.3. Cell viability and LDH release
The viability (ATP) and cytotoxicity (LDH) screenings, using 8 dif-
ferent ENM concentrations 0,1; 0,5; 1; 5; 10; 50; 100 and 500 μg/ml
(Figs. S1–S3), were conducted in order to ﬁnd an optimal exposure dose
for 48-h nanomaterial exposures.
Cell viability, by quantitation of ATP was measured after 48 h ex-
posures to eight diﬀerent ENM concentrations, with CellTiter-Glo,
Luminescent Cell Viability Assay (Promega Corporation, Madison, WI,
USA). Cytotoxicity, based on the LDH release after 48 h exposures was
measured from the supernatants with Cytotoxicity Detection Kit PLUS
(LDH) (Roche Diagnostics GmbH, Mannheim, Germany, Figs. S1–S3).
Based on the results from both assays, 10 μg/ml concentration was
chosen for inducing low levels of cytotoxicity and high cell viability.
3.4. Sample collection and extraction
DNA and mRNA were extracted and puriﬁed using Qiagen AllPrep
96 DNA/RNA extraction kit (Qiagen, Germany), following the protocol
provided by the manufacturer.
Qiagen miRNeasy 96 extraction kit (Qiagen, Germany) was used to
extract and purify miRNA from the exposed cells. RNA quality and
quantity were conﬁrmed by NanoDrop (ND-1000, Thermo Fisher
Scientiﬁc Inc., Wilmington, NC, USA) and Bioanalyzer (Agilent
Technologies, USA). Based on the RNA integrity values, the RNA sam-
ples with high RIN values (> 9) were used in microarray analyses.
3.5. Microarray sample processing
mRNA transcriptome assay was performed as instructed by Agilent
Quick Amp, two-color microarray-based gene expression analysis la-
beling protocol. 100 ng of dried total RNA was resuspended to 1,5 μl of
puriﬁed water, and labeled with Cy3 or Cy5 dyes (Agilent, USA), and
hybridized to Agilent SurePrint G3Human GE 8x60K DNA microarrays.
Slides were scanned with Agilent scanner model G2505C, and data was
extracted with Agilent feature extraction software (V11.5.1.1).
miRNA assays were performed according to the protocol provided
by the manufacturer (miRNA Microarray System with miRNA Complete
Labeling and Hyb Kit, Agilent). 100 ng of dried samples were re-
suspended in 2 μl of puriﬁed water and labeled with Cyanine 3-pCp dye
and hybridized to Agilent SurePrint G3 Unrestricted Human
miRNA_V21 8x60K microarrays. Slides were scanned with Agilent
scanner model G2505C, and data was extracted with Agilent feature
extraction software (V11.5.1.1).
Microarray data have been deposited in ArrayExpress database and
are accessible through ArrayExpress accession numbers: E-MTAB-6396,
E-MTAB-6396 and E-MTAB-6397.
3.6. Genome-wide DNA methylation
DNA was extracted together with RNA using Qiagen AllPrep 96
DNA/RNA extraction kit (Qiagen, Germany). 500 ng of DNA was bi-
sulﬁte converted with the EZ-96 Methylation Kit (Zymo Research
Corporation) according to the manufacturer's instructions. Bisulﬁte-
treated DNA was ampliﬁed, fragmented and hybridized to the
HumanMethylation450 BeadChip (Illumina) according to standard
Illumina protocol and imaging was performed using Illumina iScan
scanner.
3.7. Processing of each molecular layer (MRNA, MIRNA, DNA
methylation)
For each cell line and each analyzed molecular level, data was im-
ported and analyzed as described in the following.
3.8. mRNA
mRNA expression raw median values data from
AgilentSurePrintG3_Human_GE_v3_8x60K were imported using limma
read.maimages function. A quantile-based strategy was used to ﬁlter
out low quality probes based on the value of negative control probes. In
particular, probes having value higher than the 90% quantile of nega-
tive control probes in at least two samples were considered for sub-
sequent analytical steps. Expression values were then log(2) trans-
formed and normalized between samples using quantile normalization.
Two rounds of batch correction using ComBat method from package
SVA (Leek et al., 2012) were performed to eliminate the eﬀect of la-
beling and slide. Multiple probes mapping to the same REFSEQ entry
were summarized by the median value.
A limma based approach was employed in order to statistically es-
timate diﬀerences in average expression levels between each nanoma-
terial exposure and the corresponding controls.
3.9. miRNA
Raw median values data from Agilent microarrays were imported
using limma read.maimages function. Probes were ﬁltered in order to
keep only probes detected for at least the 50% +1 samples in at least
one treatment group. Expression values were log(2) transformed and
then quantile normalized among samples. Probes were mapped to
target miRNA by taking median value of probes for each target miRNA.
Batch eﬀect analysis revealed the presence in the dataset of a technical
batch eﬀect related to the array id. Batch eﬀects correction was per-
formed using ComBat method from the package SVA (Leek et al., 2012).
Finally, a limma model was applied to statistically estimate diﬀerence
in average miRNA expression.
3.10. CpG methylation
Raw methylation data ﬁles from Illumina Inﬁnium 450 k array were
imported with minﬁ package (Aryee et al., 2014). Data was then nor-
malized using Subset-quantile Within Array Normalization (SWAN)
(Makismovic et al., 2012) and represented as M-values. CpG probes
were then ﬁltered by a) removing all CpG probes with a detection p-
value higher than 0,01 in at least on sample, b) removing all probes
containing single nucleotide polymorphisms at the interrogation or the
elongation site and c) removing all probes belonging to the set of known
cross-hybridizing probes of the employed platform (Chen et al., 2013).
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Batch eﬀects evaluation was performed by detecting the presence of
surrogate variables with sva function from SVA package. After esti-
mating these variables, their value was discretized into n_samples^(1/3)
bins using the discretize function from infotheo package (Meyer et al.,
2008) and corrected using ComBat method from the package SVA (Leek
et al., 2012). Finally a limma model was employed in order to statis-
tically estimate diﬀerences in average methylation levels between each
nanomaterial exposure and the corresponding controls (Smyth, 2005).
3.11. Multi-omics analysis
Integrative analysis of the three assayed datasets was performed for
each exposure in each cell using SMITE toolkit (Wijetunga et al., 2017).
This tool allows to rank genes by integrating results from diﬀerential
analyses performed on one or more “modiﬁer” layers.
UCSC genes were used as a reference point in this task. p-Values and
fold changes were associated to each gene using the results of the
mRNA diﬀerential analysis. In case of multiple transcript mapping to
the same gene we took values from the transcript having the lowest p-
value.
For each gene, two regulatory regions based on its genomic co-
ordinates and the transcription orientation were deﬁned: the promoter
region, deﬁned as 1 kb region ﬂanking the transcription start site
[TSS− 1 kb, TSS+1 kb], and the gene body region, deﬁned as the
region spanning from TSS+ 1 kb to the transcription termination site
(TES) [TSS+1 kb, TES]. A set of CpGs from the methylation layer and a
set of miRNAs from the miRNA analysis were associated to each one of
these regulatory regions. CpGs were associated to promoters or bodies
by using their genomic position, while miRNA were assigned to all gene
bodies in their set of target genes, computed as the top 10% scoring
target genes, based on targetScan t-scores (Agarwal et al., 2015). For
each gene region, the fold changes and weighted p-values from me-
thylation diﬀerential analyses of all CpGs associated to the region were
considered. These latter were respectively summarized by using the
Stouﬀer method on the values, weighted by the CpG distance from the
TSS. The same operation was performed on values from miRNA dif-
ferential analysis but weighting values with the Sidak method. Next,
miRNA and methylation p-values were logit transformed and rescaled
using expression p-values as reference distribution.
Finally, genes were assigned with a score obtained by integrating
the expression p-value and fold-change with the same values from the
two modiﬁcation layers using the weights provided in Table 2. The
output of this integration step on each exposure is reported in (Scala
et al., 2018). Finally, functional modules enriched for high scoring
genes (p-value<0.01), were obtained by using a SpinGlass algorithm
with 1000 randomizations on the Reactome (Croft et al., 2010) inter-
action network.
3.12. MOA deﬁnition
For each exposure in each cell-line, the list of the altered KEGG
pathways was derived as follows. For each exposure, the set modG
obtained by taking the union of genes constituting enriched functional
modules was considered. The direction of modiﬁcation layers in the
associated regulatory regions was used to partition modG in two sub-
sets, modG_ep and modG_not_ep. modG_ep was deﬁned as the set of up-
regulated genes with hypo-methylated promoter or targeted by down-
regulated miRNAs along with the set of down-regulated genes with
hyper-methylated promoter or up-regulated targeting miRNAs.
modG_ep_not_ep was deﬁned as the complement of modG_ep with respect
to modG. Each of these three sets with enriched KEGG pathways was
annotated using the enrichKEGG function from clusterProﬁler package
(Yu et al., 2012) with a p-value threshold of 0.05, thus deriving three
sets of pathways modG_path, modG_ep_Path and modG_not_ep_Path. A
positive or negative sign was associated to each computed pathway by
deriving the sign of the median expression fold-change of the enriched
genes. Distance between diﬀerent exposures was computed in terms of
shared activated pathways. In particular for a pair of exposures A and B,
the distance between A and B was deﬁned as dist(A,B)= 1− [jacc_up
(A,B)+ jacc_down(A,B)]/2, where jacc_up(A,B) and jacc_down(A,B) are
respectively the jaccard indices computed on common positive and
common negative activated pathways between A and B.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.impact.2018.05.003.
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